Work with us
Explore a research collaboration
For investigators and research teams. See what NWPharmaTech has published about the CHR-P programme, with sources and limitations, build an agenda of points to discuss, and prepare a brief. No account is needed to explore the information or prepare a brief.
The agenda, brief and online enquiry need JavaScript. Every card and its sources are listed below, and research collaboration enquiries can be made through the Contact page.
1 Your focus optional
Answers only highlight the most relevant cards on this page. They are not sent anywhere unless you include them in an enquiry, and they are never put in shared links.
2 Relevant public information
Each card is taken from the Programme Room and the Evidence library, with its sources and limitations. Company statements and your own questions are always kept apart.
Clinical need and existing evidence
What published research says about people at clinical high risk of psychosis.
-
Finding NWPharmaTech public informationMatches your answers
An updated meta-analysis estimated that about one in four people identified as CHR-P (pooled estimate, 25%) developed psychosis within three years.
Related stage: Stage 1 · Clinical need — stage work status: Background
Sources and limitations (1)
Salazar de Pablo et al. — probability of transition to psychosis (updated meta-analysis), JAMA Psychiatry
Evidence library entry · Original source: DOI · Original source: PubMed
-
Limitation NWPharmaTech public informationMatches your answers
The pooled estimate and the separate Kaplan–Meier series are different analyses and are not combined. Estimates span services and criteria; individual risk varies.
Related stage: Stage 1 · Clinical need — stage work status: Background
Sources and limitations (1)
Salazar de Pablo et al. — probability of transition to psychosis (updated meta-analysis), JAMA Psychiatry
Evidence library entry · Original source: DOI · Original source: PubMed
-
Finding NWPharmaTech public informationMatches your answers
In England, psychological therapy is the recommended first step. NICE advises against antipsychotics to prevent psychosis in this group.
Related stage: Stage 1 · Clinical need — stage work status: Background
Sources and limitations (2)
NICE CG155 — psychosis and schizophrenia in children and young people
NICE CG178 — psychosis and schizophrenia in adults
-
Finding NWPharmaTech public informationMatches your answers
No preventive intervention has been shown to work better than the others.
Related stage: Stage 1 · Clinical need — stage work status: Background
Sources and limitations (1)
Davies et al. — network meta-analysis of preventive interventions, World Psychiatry
Evidence library entry · Original source: DOI · Original source: PubMed
Formulation and absorption
What is known about giving cannabidiol by mouth, and about the NWPT-SM32300 softgel.
-
Finding NWPharmaTech public informationMatches your answers
Cannabidiol dissolves poorly in water. Taken by mouth while fasting, only about 6% of a dose is estimated to reach the bloodstream, and food changes absorption markedly (research on other CBD products).
Related stage: Stage 2 · Formulation — stage work status: Completed
Sources and limitations (2)
Perucca and Bialer — oral cannabidiol bioavailability (review), CNS Drugs
Evidence library entry · Original source: DOI · Original source: PubMed
Taylor et al. — Phase 1 study of purified CBD, including a food-effect arm, CNS Drugs
Evidence library entry · Original source: DOI · Original source: PubMed
-
Finding NWPharmaTech public informationMatches your answers
NWPT-SM32300 is a 300 mg softgel whose contents are designed to disperse into very small droplets in the gut.
Related stage: Stage 2 · Formulation — stage work status: Completed
Sources and limitations (1)
Science — what is known and what remains open
-
Limitation NWPharmaTech public informationMatches your answers
Whether this formulation gives more consistent absorption than other CBD products. Phase 1 measured absorption; its results have not been published. How much reaches the brain has not been measured.
Related stage: Stage 2 · Formulation — stage work status: Completed
Sources and limitations (2)
Phase 1 registration: NCT07186283 and ISRCTN25163383
Evidence library entry · Original source: ClinicalTrials.gov · Original source: ISRCTN
Science — what is known and what remains open
The Phase 1 study
The completed study in healthy volunteers, and what it can and cannot show.
-
Finding NWPharmaTech public informationMatches your answers
14 healthy adult volunteers; randomised, open-label, three-period crossover.
Related stage: Stage 3 · Phase 1 — stage work status: Completed
Sources and limitations (1)
Phase 1 registration: NCT07186283 and ISRCTN25163383
Evidence library entry · Original source: ClinicalTrials.gov · Original source: ISRCTN
-
Limitation NWPharmaTech public informationMatches your answers
Study activity ended on 10 December 2025. Results have not yet been published.
Related stage: Stage 3 · Phase 1 — stage work status: Completed
Sources and limitations (2)
Phase 1 registration: NCT07186283 and ISRCTN25163383
Evidence library entry · Original source: ClinicalTrials.gov · Original source: ISRCTN
Study progress — Phase 1 milestones
-
Limitation NWPharmaTech public informationMatches your answers
Healthy volunteers and single doses: measures absorption and short-term tolerability, not effectiveness in clinical high risk of psychosis.
Related stage: Stage 3 · Phase 1 — stage work status: Completed
Sources and limitations (1)
Phase 1 registration: NCT07186283 and ISRCTN25163383
Evidence library entry · Original source: ClinicalTrials.gov · Original source: ISRCTN
The planned Phase 2B study
Proposed research: its aims and current status.
-
Finding NWPharmaTech public informationMatches your answers
If it goes ahead: whether NWPT-SM32300 shows a dose response, changes symptoms, and is safe and tolerable in people at clinical high risk of psychosis.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (1)
Study progress — current stage, aims and oversight
-
Finding NWPharmaTech public informationMatches your answers
Status: planned. Not recruiting. The protocol is being finalised.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (2)
Study progress — current stage, aims and oversight
Study progress — Phase 2B protocol finalisation (in progress)
-
Finding NWPharmaTech public informationMatches your answers
The Phase 2B study can start only after regulatory and research ethics approval.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (1)
Study progress — current stage, aims and oversight
-
Limitation NWPharmaTech public informationMatches your answers
Oversight arrangements for the Phase 2B study have not yet been published.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (1)
Study progress — current stage, aims and oversight
-
Finding NWPharmaTech public informationMatches your answers
A larger UK trial of cannabidiol in this group (CANTOP-RCT) did not start owing to challenges in securing supply of the study drug, which is one reason this question remains open.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (1)
Bhattacharyya S, Davies C, et al. — Cannabidiol as a treatment for patients who are clinically at high risk of developing psychosis: learnings from the CANTOP-RCT, NIHR Journals Library
Evidence library entry · Original source: DOI · Original source: PubMed
-
Limitation NWPharmaTech public informationMatches your answers
A small 21-day study of another CBD product in this group was published in 2024. Its findings are early, have not been confirmed in a larger trial, and do not apply directly to NWPT-SM32300.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (1)
Bhattacharyya et al. — 21-day symptom study of another CBD product in clinical high risk, World Psychiatry
Evidence library entry · Original source: DOI · Original source: PubMed
Open questions
What is not yet known.
-
Open question Unresolved NWPharmaTech public informationMatches your answers
Does NWPT-SM32300 reduce symptoms in people at clinical high risk?
Not established. It would take the results of a pre-specified clinical study such as the planned Phase 2B.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (2)
Study progress — current stage, aims and oversight
Bhattacharyya et al. — 21-day symptom study of another CBD product in clinical high risk, World Psychiatry
Evidence library entry · Original source: DOI · Original source: PubMed
-
Open question Unresolved NWPharmaTech public informationMatches your answers
Is there a dose response, and which dose would be best?
Not established. Dose response is one of the planned study’s aims.
Related stage: Stage 5 · Phase 2B — stage work status: Proposed
Sources and limitations (1)
Study progress — current stage, aims and oversight
-
Open question Unresolved NWPharmaTech public informationMatches your answers
Is it safe and well tolerated in this population?
Not established. Phase 1 involved healthy volunteers and single doses only.
Related stage: Stage 3 · Phase 1 — stage work status: Completed
Sources and limitations (1)
Phase 1 registration: NCT07186283 and ISRCTN25163383
Evidence library entry · Original source: ClinicalTrials.gov · Original source: ISRCTN
-
Open question Unresolved NWPharmaTech public informationMatches your answers
How much reaches the brain?
No study has measured it.
Related stage: Stage 2 · Formulation — stage work status: Completed
Sources and limitations (1)
Science — what is known and what remains open
-
Open question Unresolved NWPharmaTech public informationMatches your answers
Can transition to psychosis be delayed or prevented?
A longer-term question needing a separately powered trial with long follow-up.
Related stage: Stage 6 · Longer term — stage work status: Open question
Sources and limitations (1)
Davies et al. — network meta-analysis of preventive interventions, World Psychiatry
Evidence library entry · Original source: DOI · Original source: PubMed
Exploring a collaboration
What this page can and cannot do, and questions you may want to raise.
-
Website statement NWPharmaTech public informationMatches your answers
This page brings together public information to help you prepare a conversation. It does not offer a study protocol, study medicine, sponsorship, funding or access to unpublished data. Selecting a card does not commit you or NWPharmaTech to anything.
-
Question for discussion Suggested wording for your questionMatches your answers
How does my research question relate to the aims of the planned Phase 2B study?
-
Question for discussion Suggested wording for your questionMatches your answers
Who could discuss methods or study-design questions with me?
-
Question for discussion Suggested wording for your questionMatches your answers
When are the Phase 1 results expected to be published?
-
Question for discussion Suggested wording for your questionMatches your answers
What should a collaboration enquiry include so that NWPharmaTech can consider it?
3 Your discussion brief
Built from your agenda. Print it or save it as a PDF, or copy a link that recreates the selected topics and cards. A copied link never includes your questions, focus answers or contact details.
4 Contact about collaboration
Please do not include confidential or unpublished information, patient information or health data. This is not a diagnosis service, crisis line, or trial enrolment portal.
Online enquiries need JavaScript. To contact us about a research collaboration, email [email protected] with the subject “Research collaboration”, or see the Contact page.
Content version wwu-1 · public information reviewed 26 September 2026. Sources come from the Evidence library and the study records. See the privacy notice.